Statement on Improving Access to Healthcare and Pharmaceuticals

The Denka Group recognizes the issue of medical access as an important human rights issue. In developing countries, many people face difficulties in receiving appropriate medical care due to vulnerable medical infrastructures and restricted access to medical care. The spread of infectious diseases is particularly serious, and a vicious cycle is created in which further infections occur and many people lose their lives because tests are not conducted even for diseases that can be cured with early diagnosis. Improving medical access will help reduce such people and protect the lives and livelihoods of people around the world. The Denka Group will continue to contribute to improving access to pharmaceuticals and ultimately medical access for all people, including those in developing countries, to achieve the materiality of "extending healthy life expectancy and correcting health disparities" in our management plan through our diagnostic reagents and healthcare services businesses. In promoting the improvement of access to pharmaceuticals and medical care, we are providing Ebola antigen rapid test kits to the Equateur Province of the Democratic Republic of the Congo at a special price with the cooperation of JICA.

Efforts in Developing Countries for Pharmaceutical Development

The Denka Group has provided an Ebola virus antigen rapid test kit, co-developed with Professor Yoshito Takada of Hokkaido University, to the Democratic Republic of the Congo (DRC) through JICA. The kit has been used for initial testing during several outbreaks of Ebola hemorrhagic fever in the DRC and has contributed to preventing the spread of the disease. The kit can provide results in about 10 minutes, can be stored at room temperature, and does not require any special equipment or devices, making it suitable for use in remote areas away from urban centers where medical facilities are not adequately equipped. Following the approval for manufacturing and marketing in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2021, the kit is expected to receive formal approval for use from the National Institute of Biomedical Research of the DRC in 2024. It is expected to contribute to the prevention of infectious diseases by enabling rapid diagnosis in the event of Ebola hemorrhagic fever patients and improving access to pharmaceuticals and medical care in developing countries.

Proper Promotion Activities of Pharmaceuticals

Denka complies with the "Code of Practice" established by the Japan Pharmaceutical Manufacturers Association and the "In Vitro Diagnostic Reagents Promotion Code" established by the Japan Clinical Reagent Manufacturers Association. Denka takes all responsibility for promotion, including the conduct of medical information representatives, establishes an internal system for conducting appropriate promotion, and engages in responsible advertising, marketing, and sales promotion of pharmaceutical products.

• ※Products including medical use pharmaceuticals and in vitro diagnostic products including inspection kits are referred to as “pharmaceuticals”.

Promotional codes for in vitro diagnostics and pharmaceutical products 1. Denka's Responsibilities

1. Appoint appropriate persons as medical representatives and continue to provide education and training.
2. Provide information on indications (purpose of use), dosage and method of use (method of operation), or sensitivity, accuracy, reproducibility (performance), correlation, etc. in a proper manner based on data with a clear scientific basis.
3. Accurately and promptly collect and communicate pharmaceutical information.
4. Establish an internal system to ensure that activities are conducted in compliance with relevant laws and regulations and voluntary regulations.

Denka has established a Code of Conduct in accordance with the Promotion Code to ensure higher ethical standards and transparency in exchanges with all stakeholders, including medical professionals, medical institutions, and patient organizations, and to address responsible advertising, marketing, and sales promotion and provide accurate information. For example, as a company that plays a part in medical care, we conduct responsible information activities for pharmaceuticals and recognize that printed materials for promotion, advertisements in specialized magazines (paper), promotional audiovisual materials such as slides and VTR, and other promotional materials are important means of providing pharmaceutical information. Furthermore, as stated in the above 1., we continue to conduct educational training regarding these Promotion Codes and the relevant laws and regulations of each country for all employees involved in pharmaceuticals.

When creating and using these materials, we comply with the Pharmaceutical and Medical Device Act (Law for Ensuring Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices) and the following guidelines: "Guidelines on Information Provision Activities for Medical Use Pharmaceuticals," "Guidelines on Information Provision Activities for In Vitro Diagnostics," and "Guidelines on Creating Product Information Summaries for Medical Use Pharmaceuticals," as well as the codes of conduct for promotion of medical use pharmaceuticals and in vitro diagnostics that conform to these laws and guidelines. We also conduct appropriate and responsible promotion activities based on high ethical standards when selling and advertising pharmaceuticals.

Quality and safety of pharmaceuticals